Use of Oral Budesonide in the Management of Protein-Losing Enteropathy After the Fontan Operation

Annals of Thoracic Surgery

Volumn 89, Issue 3, 2010, Pages 837-842

  Thacker, Deepika ^a   Patel, Akash ^a   Dodds, Kathryn ^a   Goldberg, David J ^a   Semeao, Edisio ^a   Rychik, Jack ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; HEPARIN; INFLIXIMAB; OCTREOTIDE; PREDNISONE; SERUM ALBUMIN; SILDENAFIL;

ACNE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BILATERAL AXILLARY LYMPHADENOPATHY; CHILD; CLINICAL ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FENESTRATION; FONTAN PROCEDURE; HEART HEMODYNAMICS; HUMAN; HYPOALBUMINEMIA; INFECTION; LOW DRUG DOSE; LYMPHADENOPATHY; MALE; MOON FACE; OSTEOPOROSIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; PULMONARY ARTERY; SCHOOL CHILD; SKIN CELLULITIS; SKIN DISEASE; STENT; URINARY TRACT INFECTION; WEANING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; FEMALE; FONTAN PROCEDURE; HUMANS; MALE; PROTEIN-LOSING ENTEROPATHIES; SERUM ALBUMIN; YOUNG ADULT;

EID: 76749146029     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2009.09.063     Document Type: Article

References (34)

1. Crupi G., Locatelli G., Tiraboschi R., Villani M., De Tommasi M., and Parenzan L. Protein-losing enteropathy after Fontan operation for tricuspid atresia (imperforate tricuspid valve). Thorac Cardiovasc Surg 28 (1980) 359-363
2. Mertens L., Hagler D.J., Sauer U., Somerville J., and Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 115 (1998) 1063-1073
3. Feldt R.H., Driscoll D.J., Offord K.P., et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 112 (1996) 672-680
4. Rychik J., and Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 90 (2002) 672-674
5. Ostrow A.M., Freeze H., and Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 82 (2006) 695-700
6. Rychik J., Piccoli D.A., and Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 68 (1991) 819-821
7. Therrien J., Webb G.D., and Gatzoulis M.A. Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation?. Heart 82 (1999) 241-243
8. Zellers T.M., and Brown K. Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol 17 (1996) 115-117
9. Spencer C.M., and McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50 (1995) 854-872
10. Thomsen O.O., Cortot A., Jewell D., et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 339 (1998) 370-374
11. Campieri M., Ferguson A., Doe W., Persson T., and Nilsson L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 41 (1997) 209-214
12. Edsbacker S., and Andersson T. Pharmacokinetics of budesonide (Entocort EC capsules for Crohn's disease. Clin Pharmacokinet 43 (2004) 803-821
13. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
14. Petersen J.W., and Felker G.M. Inflammatory biomarkers in heart failure. Congest Heart Fail 12 (2006) 324-328
15. Shimizu T., Nagata S., Fujii T., et al. Enhanced production of interferon-gamma as a possible cause of protein-losing enteropathy after modified Fontan operation. J Pediatr Gastroenterol Nutr 37 (2003) 504-507
16. Bode L., Eklund E.A., Murch S., and Freeze H.H. Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy. Am J Physiol Gastrointest Liver Physiol 288 (2005) G1015-G1023
17. Bode L., Murch S., and Freeze H.H. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem 281 (2006) 7809-7815
18. Murch S.H., Winyard P.J., Koletzko S., et al. Congenital enterocyte heparan sulphate deficiency with massive albumin loss, secretory diarrhoea, and malnutrition. Lancet 347 (1996) 1299-1301
19. Vyas H., Driscoll D.J., Cabalka A.K., Cetta F., and Hagler D.J. Results of transcatheter Fontan fenestration to treat protein losing enteropathy. Catheter Cardiovasc Interv 69 (2007) 584-589
20. Uzun O., Wong J.K., Bhole V., and Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 82 (2006) e39-e40
21. Brancaccio G., Carotti A., D'Argenio P., Michielon G., and Parisi F. Protein-losing enteropathy after Fontan surgery: resolution after cardiac transplantation. J Heart Lung Transplant 22 (2003) 484-486
22. Rychik J., and Spray T.L. Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 5 (2002) 3-11
23. Cohen M.I., Rhodes L.A., Wernovsky G., Gaynor J.W., Spray T.L., and Rychik J. Atrial pacing: an alternative treatment for protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 121 (2001) 582-583
24. Sierra C., Calleja F., Picazo B., and Martinez-Valverde A. Protein-losing enteropathy secondary to Fontan procedure resolved after cardiac transplantation. J Pediatr Gastroenterol Nutr 24 (1997) 229-230
25. Satomi G., Yasukochi S., Harada Y., and Takeuchi M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. Heart 76 (1996) 90-91
26. Mertens L., Dumoulin M., and Gewillig M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. Br Heart J 72 (1994) 591-592
27. Rothman A., and Snyder J. Protein-losing enteropathy following the Fontan operation: resolution with prednisone therapy. Am Heart J 121 (1991) 618-619
28. Kelly A.M., Feldt R.H., Driscoll D.J., and Danielson G.K. Use of heparin in the treatment of protein-losing enteropathy after Fontan operation for complex congenital heart disease. Mayo Clin Proc 73 (1998) 777-779
29. Ryerson L., Goldberg C., Rosenthal A., and Armstrong A. Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation. Am J Cardiol 101 (2008) 248-251
30. Bhagirath K.M., and Tam J.W. Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation. Ann Thorac Surg 84 (2007) 2110-2112
31. Elsayed E., and Becker R.C. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 15 (2003) 11-18
32. Hamada Y., Kawachi K., Nakata T., Kohtani T., Takano S., and Tsunooka N. Antiinflammatory effect of heparin-coated circuits with leukocyte-depleting filters in coronary bypass surgery. Artif Organs 25 (2001) 1004-1008
33. Narkewicz M.R., Sondheimer H.M., Ziegler J.W., et al. Hepatic dysfunction following the Fontan procedure. J Pediatr Gastroenterol Nutr 36 (2003) 352-357
34. Friedrich-Rust M., Koch C., Rentzsch A., et al. Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. J Thorac Cardiovasc Surg 135 (2008) 560-567